SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (732)9/10/1997 7:39:00 AM
From: tonyt   of 2173
 
And just where are the shares that are being sold coming from henry? As you said, its not the little guy.

> When the diabetes deal is announced...

Well, according to thestreet:
" With almost 33 million shares outstanding, the company has a healthy valuation of over half a billion and no product sales. But, if the murmuring is right, the Ligand deal, with what would be its eighth partner, could be a big one. Since the third week of August, Ligand's stock is up about 35%, trading Monday at 16. "
"[Ligand] is on some people's radar screens. A diabetes deal and cancer data puts it on a whole lot more," says Rich van den Broek, an analyst for Ligand banker Hambrecht & Quist. He cautions that completing a "deal always takes longer than you think."

> Tony, You have moaned and groaned

And try to keep this discussion civil. You show a bias whenever someone disagrees with you.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext